24.01.2018
- Sanofi is boosting its presence in blood disorders through the acquisition of Bioverativ, the former hemophilia business of major US biotech Biogen, which was spun out in February...
26.07.2017
- Shire has obtained exclusive worldwide rights from Novimmune for a bi-specific antibody that is currently in pre-clinical development for treating patients with the blood disorders...
16.05.2017
- Major US drugmaker Pfizer is collaborating with Sangamo Therapeutics to develop and commercialize gene therapy programs for the rare blood disorder hemophilia A. The agreement...
20.05.2016
- US biotechnology company Biogen is to spin off its hemophilia business into an independent, publicly traded business. Biogen said it believes the creation of two separate companies...
16.04.2015
- Bayer HealthCare has announced plans to invest $100 million in a product testing facility at its Berkeley, California, US manufacturing site to support the next generation of...
12.03.2014
- BayerHealthcare plans to invest more than €500 million at its sites in Wuppertal and Leverkusen, Germany, to expand capacity for production of its recombinant factor VIII...
